Clinical Trial Update: Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab [Phase 2]

View source ↗

Summary

A Phase 2 melanoma trial is investigating adjuvant treatment decisions based on pathological response to neoadjuvant nivolumab. The study involves Stage III mel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• OPDIVO (nivolumab)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Melanoma Stage III, Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING